---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-243745"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2022-09-13T23:59:59+00:00"
generated_at: "2026-06-23T09:56:01.890538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Vaccinex presents neoadjuvant pepinemab combo data at ESMO; triple therapy shows 62.5% pCR in Stage III melanoma

## Summary
- Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.
- Doublet pepinemab/nivolumab showed 25% pCR; pepinemab/ipilimumab 12.5% pCR; nivolumab alone 28.5% pCR.
- Triple combination demonstrated significantly improved recurrence-free survival vs doublets (logrank p=0.0097).
- All patients underwent surgery without delay; Grade 3 AEs were manageable (5/8 in triple arm).
- Correlative biomarker data to be presented at 2022 SITC; further studies needed to confirm durability.

## SEC filing metadata
- accession: 0001193125-22-243745
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2022-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/0001193125-22-243745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/d402023d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-243745
- JSON: https://secwatch.observer/filing/0001193125-22-243745.json
- Plain text: https://secwatch.observer/filing/0001193125-22-243745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.